Aerie Pharmaceuticals, Inc.

2030 Main Street, Suite 1500
United States

Tel: 949.526.8700
Fax: 949.526.8787

Show jobs for this employer

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Aerie's first product, once-daily Rhopressa® (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA) in December 2017. A link to the full product label is available on the Aerie website at Aerie’s second product candidate, once-daily RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed-dose combination of Rhopressa® and widely prescribed PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1. The RoclatanTM NDA submission is expected to take place in the second quarter of 2018. Aerie is also focused on global expansion and the growth of its pipeline in ophthalmology.  These development efforts include preclinical studies of AR-13503, a small molecule inhibitor of Rho kinase and protein kinase C that has demonstrated significant reduction in lesion size associated with wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in animal models, and AR-1105, a dexamethasone steroid with the potential to treat DME. Aerie is also exploring drug delivery opportunities using a bio-erodible polymer sourced from DSM that may provide sustained release of small molecules such as AR-13154 to the retina and through exclusive rights to PRINT® technology for ophthalmic indications, providing a manufacturing platform for precisely-sized implants.

Stock Symbol:  AERI

Stock Exchange:  NASDAQ

Click here to learn more about Rhopressa®

Our VISIONaerieS® have been working to develop a new class of glaucoma medication that targets the diseased trabecular meshwork, an unmet medical need.

310 articles with Aerie Pharmaceuticals, Inc.